Get started
Author

Katrin Jack

Observed name: Jack, Katrin
Observed institution: Galderma (Switzerland)
ORCID: 0009-0006-0814-2427
Observed ORCID: 0009-0006-0814-2427
OpenAlex ID: A5108967272
Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany
2024 · Nicholas Durno, Pablo Arija, et al. · Journal of Dermatological Treatment · 6
PDF
Patients’ Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)
2025 · Jonathan I. Silverberg, Dina Filipenko, et al. · Patient · 3
PDF
Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis
2026 · Andrew E. Pink, John Houghton, et al. · Dermatology and Therapy · 2
PDF
Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis
2026 · Gil Yosipovitch, Katarzyna Borkowska, et al. · Dermatology and Therapy · 1
PDF
Development of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 Trial
2026 · Jonathan I. Silverberg, Patrick Daniele, et al. · Dermatology and Therapy
PDF
Patient preferences for prurigo nodularis treatment: a discrete choice experiment
2026 · Anthony Bewley, Sarina Elmariah, et al. · Journal of Dermatological Treatment
Patient preferences for prurigo nodularis treatment: a discrete choice experiment
2026 · Anthony Bewley, Sarina Elmariah, et al. · Figshare
691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment
2024 · Jorge Puelles, Pablo Arija, et al. · British Journal of Dermatology
Works count: 9
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type